Einige Inhalte dieser Seite sind nur für Abonnenten sichtbar.       Anmelden     oder      Jetzt abonnieren!

Archiv: Alle Kategorien

Richemont announces the appointment of a Non-executive Co-Deputy Chairman of its Board of Directors » Report
BioVersys reports half-year 2026 results: BV100 pivotal RIV-TARGET trial actively recruiting, alpibectir Phase 2b/c underway, operations funded into 2028 » Report
Medacta Group SA: Medacta Group SA reports above-market revenue growth of 9.7% in constant currency1 with a robust adjusted EBITDA margin of 27.8% in c.c.1 in H1 2026 » Report
DocMorris lanciert Privatplatzierung einer Wandelanleihe von etwa CHF 100 Millionen mit Fälligkeit 2031 zur Finanzierung des vorzeitigen Rückkaufs der Wandelanleihe 2028 » Report
Logitech Shareholders Approve All Board Proposals, Including Increased Dividend, at 2026 Annual General Meeting » Report
Avolta extends long-term travel retail contracts across four Mexican airports » Report
Temenos publishes its 2026 Interim Report » Report
Guten Abend: Daily SMI -1,55% 14057 +++ Top ABBN +2,5% SCMN +2,4% NESN +2,1% UBSG +1,4% GEBN PGHN +0,8% Flop NOVN -10,9% AMRZ -2,6% ALC -2% SREN -1,6 LOGN -1,5% ZURN -1% +++ VSMI +4,90% 14.20 +++ DAX +0,00% 26007 +++ Strasse schwächer bis leichter
SwissAtMid Monthly Report - 08/2026 » Report
Three steps and a bake-off: Nestlé launches a new generation of dessert culinary solutions » Report
ABB und Rolls-Royce SMR unterzeichnen Vereinbarung zu Small Modular Reactors » Report
ABB and Rolls-Royce SMR sign agreement on nuclear small modular reactor collaboration » Report
Logitech - Logitech Unveils MX Keypad for Developers: The Customizable Multi-App AI Control Center » Report
Redemption of UBS Group AG senior unsecured notes » Report
SCHWEIZER INDIKATIONEN: Der SMI notiert vorbörslich schwächer. Freundliche Roche PS, Swiss Re, schwache Novartis, feste Oerlikon, Sandoz, SoftwareOne, freundliche SFS fallen auf. Quelle cash Insider
Neue Eidgenössische Anleihe » Report
Sandoz invests in new drug substance facility in Ljubljana, Slovenia, to expand biosimilar manufacturing capacity » Report
Newron Pharmaceuticals S.p.A. - Newron reports subscription for EUR 5.5 million of shares by investor group as part of up to EUR 38 million total financing to advance Phase 3 evenamide program » Report
Newron Pharmaceuticals S.p.A. - Investorengruppe zeichnet Newron-Aktien im Wert von EUR 5.5 Mio. als Teil der Gesamtfinanzierung von bis zu EUR 38 Mio. zur Fortführung des Phase-3-Entwicklungsprogramms von Evenamide » Report
Sandoz hosts Capital Markets Day and unveils Bio100 ambition – maximising Sandoz value in its golden decade for biosimilars » Report